Ventyx Biosciences, Inc.
CIK 0001851194
Revenue (TTM)
—
Q3 Nov 2025
Net Income (TTM)
−$112.51M
+30.0% YoY
Q3 Nov 2025
EPS Diluted (TTM)
−$1.59
+40.3% YoY
Q3 Nov 2025
Gross Margin
—
Q3 Nov 2025
Operating Margin
—
Q3 Nov 2025
Net Margin
—
Q3 Nov 2025
Free Cash Flow (TTM)
−$117.28M
Q3 Nov 2025
Cash
$31.97M
Q3 Nov 2025
Total Debt
—
Q3 Nov 2025
Shares Outstanding
71.36M sh
Q3 Nov 2025
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.